Where the 19,400-case safety figure comes from

19,400 is not a trial enrolment figure — it is the cumulative count of patients treated with ChondroFiller® liquid worldwide, compiled by the manufacturer in its Version 09 Clinical Evaluation Report (CER), dated 30 April 2025. That document is the largest single safety surveillance dataset currently available for this product and forms the primary evidence base reviewed here. The London Cartilage Clinic's published evidence page independently corroborates the '>19,000 cases' total, cross-referencing the same headline outcomes.

ChondroFiller® liquid is a CE-marked Class III medical device — a category reserved for high-risk implantable products subject to the strictest EU regulatory scrutiny. It is neither a drug nor a cell therapy. The scaffold is acellular: a murine-derived Type I collagen matrix that gels in situ, recruits the patient's own progenitor cells, and biodegrades as repair tissue is deposited. In the current outpatient service pathway, it is placed under ultrasound guidance as an intra-articular injection for suitable focal knee cartilage defects.

The CER data were gathered through post-market clinical follow-up (PMCF) surveillance, the mandatory ongoing monitoring framework under EU MDR. This is regulatory-grade data collection with a defined reporting obligation — not a published randomised controlled trial, and not an independent registry. The manufacturer sponsored and assembled the surveillance. Readers should hold that origin in mind alongside the scale when weighing the safety figures that follow.

Complication and reoperation rates in context

Across the CER's 19,400+ treated cases, the reported complication rate for ChondroFiller® liquid sits at approximately 0%. That figure derives from the CER's own comparative analysis table rather than an independent randomised trial — a distinction worth noting once, and then setting aside to read the numbers.

Reoperation rates give the statistic practical weight. ChondroFiller® liquid's reported reoperation rate of 3–8% compares with microfracture at up to 41% and ACI/MACI at up to 37% reoperation alongside up to 17% complication rates. For a patient trying to gauge relative risk before a consultation, the gap between 3–8% and 41% is substantial and holds across all plausible margins of measurement uncertainty.

One adverse-event mechanism has been identified across the broader dataset: overfilling. In a published study of ChondroFiller used in intra-articular distal radius fractures, fibrous tissue formation occurred exclusively in overfilled defects; applications placed flush with the articular surface showed no such finding, and complication rates in that group did not differ significantly from controls. The implication for knee treatment is that volume precision at the time of placement is the primary modifiable risk variable — a function of technique rather than an intrinsic property of the material.

Collagen-membrane ACI registry data in 662 knees recorded graft hypertrophy in 10.7% of cases and delamination in 14.1%, figures that further contextualise the low complication signal seen in acellular scaffold approaches.

Knee outcome scores at one and three years

Two scores appear consistently in the knee-specific literature: IKDC and MOCART. The International Knee Documentation Committee (IKDC) score is a patient-reported measure of knee function and symptoms, scaled from 0 to 100, where higher scores reflect better function. MOCART is an MRI-based score that quantifies how completely a cartilage defect has been filled and how well the repair tissue integrates with the surrounding native cartilage.

Four knee clinical studies, drawn from the CER dataset, show a consistent IKDC improvement of approximately 30 points — nearly double the established Minimal Clinically Important Difference (MCID) of 16.7 points, the threshold below which a change is unlikely to be felt by the patient. In practical terms, a 30-point gain typically represents the difference between significantly limited daily activity and near-normal knee function.

The strongest individual dataset is the prospective PMCF study by Jerosch et al., which recorded a mean IKDC improvement of 32.4 points. That gain was maintained — and marginally increased — at three-year follow-up, with patients reaching a functional score of 80. Durability to three years is therefore supported by evidence; peer-reviewed knee-specific follow-up beyond five years has not yet been published.

The MOCART data add a structural dimension to this picture. Scores of 81.6–84.3 in European studies indicate greater than 80% defect filling and good tissue integration. One study tracked the trajectory from 65.3 at four weeks to 81.6 at one year — a pattern consistent with the scaffold's biology: it does not mechanically fill the defect immediately but instead supports progressive cellular repair across the first twelve months.

Repair tissue quality and why it matters

Native articular cartilage is hyaline tissue: dense, load-tolerant collagen arranged to absorb and distribute force across the joint surface. When a focal defect is repaired with fibrocartilage — the tissue produced by microfracture — the replacement is biomechanically inferior: less organised, lower in type II collagen, and prone to degradation under the repetitive loading of an active knee. Over time that difference in durability tends to show up as recurrent symptoms and, in a proportion of patients, a return to theatre.

ChondroFiller® liquid promotes hyaline-like repair tissue through acellular matrix-induced chondrogenesis. Because the scaffold recruits the patient's own progenitor cells and guides their differentiation, the result is structurally closer to the original tissue rather than a fibrous patch.

The MOCART MRI scores reported in European knee studies — 81.6 to 84.3 — capture this distinction rather than merely confirming that space has been filled. A score above 80 reflects both the degree of defect fill and the integration of new tissue with the surrounding native cartilage, which is what determines whether the repair holds under load.

This distinction carries most weight for younger or more active patients, where a repair that lasts a decade matters differently from one that provides short-term symptom relief. For a 35-year-old with a focal Grade IV defect, the quality of what fills that defect — not just whether it fills — shapes the longer-term joint trajectory.

Suitable knee patients and key contraindications

Not every painful knee is a suitable candidate, and a brief self-screen before booking an assessment can save time. The patients who tend to benefit most share a common profile: a single, structurally contained focal defect — Grade III or IV — covering up to 6 cm², with healthy cartilage at the surrounding borders and no widespread joint degeneration.

The most important contraindication is advanced osteoarthritis. ChondroFiller® is designed to repair a focal lesion within a knee that is otherwise mechanically reasonable; it is not intended for diffuse cartilage loss or Kellgren-Lawrence Grade IV OA. Cross-joint data from a hip study reinforce this boundary: patients with pre-existing Tönnis Grade 2–3 osteoarthritis had consistently poor outcomes — a signal clinical teams apply to the knee when assessing whole-joint health before proceeding.

Several other factors are likely to be explored at assessment. Significant malalignment — such as varus or valgus deformity — places uneven load across the repair site and may need to be addressed before or alongside treatment. Ligament instability and body weight above typical cartilage-surgery thresholds raise similar questions about whether the mechanical environment can support a successful repair.

Because the suitability criteria interact — defect size, OA grade, alignment, load — a consultant assessment including weight-bearing X-ray and MRI is needed to confirm whether the profile fits. These are the questions an experienced clinician will work through, not a checklist a patient can resolve alone.

Evidence gaps patients should weigh before deciding

The evidence assembled across the preceding sections is stronger than its detractors often acknowledge — 19,400 treated cases, four consistent knee studies, and a reoperation rate well below the benchmarks for both microfracture and ACI/MACI represent a credible safety signal. Three gaps, not yet named, remain.

Durability beyond three years. The longest knee-specific peer-reviewed follow-up sits at three years. Given that MOCART scores were still rising between four weeks and 12 months — from 65.3 to 81.6 — the repair tissue appears to mature progressively rather than stabilise immediately. Whether that trajectory holds, plateaus, or changes beyond three years has not been captured in published literature.

The injectable pathway's distinct footprint. The 19,400-case total spans both arthroscopic implantation and the newer ultrasound-guided injectable route. The injectable form's specific outcomes have not been independently disaggregated from the broader surveillance dataset in publicly available literature, so its separate performance profile cannot yet be read off from the wider corpus.

Limitations that compound. The manufacturer origin of the denominator and the absence of a head-to-head randomised trial — both noted earlier in this article — sit alongside the two gaps above. Taken together, patients considering this option are working with a 3-year evidence ceiling, a shared-source safety total, and no independent randomised comparator. The evidence supports a well-characterised option; it does not yet support extrapolating from the current corpus to a 10-year durability claim.

1. [1] Arthroscopic utilization of ChondroFiller gel for treatment of hip cartilage defects: 12–60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Hydrogel-Based ACI for Large Knee Cartilage Defects: 5-Year Phase III Trial. (2025). https://doi.org/10.1177/19476035251334737 https://doi.org/10.1177/19476035251334737
3. [3] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
4. [4] Collagen-membrane-covered MACI vs periosteum-covered MACI: safety registry study. (2026). https://doi.org/10.1002/ksa.70352 https://doi.org/10.1002/ksa.70352